Alnwick's Arcinova collaborates with Cramlington business to strengthen local pharmaceutical sector

Northumberland-based Arcinova is to now have access to Sterling Pharma Solutions’ scaleup and pilot plant assets, said to complement the company’s existing facilities.

Sterling Pharma Solutions is headquartered in Cramlington, 28 miles from the Arcinova site. The facilities include pilot plant assets ranging from 50lt up to 1300lt capacity, with 5-100kg batch generation capability.

The scaleup process will be executed by trained Arcinova personnel, supported by the long-established skills, infrastructure and capacity of Sterling Pharma Solutions.

Both organisations are very experienced in the provision of secure sources of supply for technically challenging projects.

Ian Shott CBE, CEO of Arcinova and investor/director at Sterling Pharma Solutions, said: “I’m delighted that Arcinova and Sterling Pharma Solutions have forged this partnership.

“By working in collaboration and combining expertise and specialist capabilities, we can offer an even wider ranging service to the global pharmaceutical and biotechnology communities and further strengthen the level of support we offer to our clients.”

Arcinova provides both integrated end-to-end solutions and standalone services to pharmaceutical and biotech companies.

It works across drug substance synthesis, drug product manufacture, CMC, bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent Active Pharmaceutical Ingredients (APIs).

Sterling Pharma Solutions is a provider of small molecule API development and manufacturing services to the global pharmaceutical industry.

Paul Quigley, head of API at Arcinova, commented: “This new capability will ensure technical transfer from grams to 100’s kilogram scale, which is a hugely exciting development for Arcinova and reflects the increased demand we have seen for our API services.

“In addition, this collaboration demonstrates the strength of North East England’s pharmaceutical sector and our ability to make an impact on a global scale.”

Launched in 2016, Arcinova has benefited from decades of investment as a key research and development centre for Sanofi and Covance.

Arcinova works with big pharma, specialty pharma and biotech companies across the globe, from established multinationals to emerging startups.

Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →